Palisade Capital Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Palisade Capital Management’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,560	Closed	-$135K	–	569
2015 Q4	$135K	Sell	4,560 -2,740	-38%	-$82.9K	﹤0.01%	517
2015 Q3	$231K	Buy	7,300 +1,550	+27%	+$74.2K	0.01%	502
2015 Q2	$340K	Buy	+5,750	New	+$406K	0.01%	492

Other funds holding PTX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Palisade Capital Management's PTX Position: Q1 2016 in Review

Palisade Capital Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2016, closing a stake of 4,560 shares — an estimated $135K sold.

Palisade Capital Management first reported a position in PTX in Q2 2015 and held it in 3 quarters. The position peaked at $340K in Q2 2015. 88 funds tracked by Wall St. Rank hold PTX as of Q1 2016.

Palisade Capital Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2016 after selling out during the quarter.
Palisade Capital Management sold 4,560 Pernix Therapeutics Holdings, Inc. shares in Q1 2016, an estimated $135K.
Palisade Capital Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 3 quarters.
Palisade Capital Management's Pernix Therapeutics Holdings, Inc. position peaked at $340K in Q2 2015.
88 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2016.

Based on Palisade Capital Management's 13F filing for Q1 2016, filed 11 May 2016.